Abstracts

PBPK MODELS OF TFV EXPOSURE IN LYMPH NODES REVEAL PERMEABILITY-LIMITED DISTRIBUTION

Despite antiretroviral (ARV) therapy, HIV persists in lymphoid tissue throughout the body. Lymph node ARV penetration is crucial for HIV treatment and eradication, but sampling these tissues is highly invasive and costly. Here, we investigate whether a novel physiologically-based pharmacokinetic (PBPK) model can predict the concentration of tenofovir (TFV) in lymph nodes of nonhuman primates…

DORAVIRINE CONCENTRATIONS AND HIV-1 RNA SUPPRESSION IN MALE AND FEMALE GENITAL FLUIDS

Residual HIV replication in reservoirs might contribute to immune activation and inflammation and constitutes a barrier to eradication. Antiretroviral distribution in male and female genital tract is required to suppress HIV replication within these compartments. We determined doravirine concentrations and HIV-1 RNA in blood plasma (BP), seminal plasma (SP) and cervicovaginal fluid (CVF) of HIV-1-infected…

PREDICTED SUCCESS OF PrEP USERS’ PREFERRED NONDAILY TENOFOVIR/EMTRICITABINE REGIMENS

Adherence is critical for effective HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), yet remains a clinical challenge. TDF/FTC PrEP users are interested in less-than-daily and event-driven dosing [PMCID: PMC7228850]. Using a published model of TDF/FTC pharmacokinetics/pharmacodynamics (PK/PD) in rectal (RT), cervical (CT), and vaginal (VT) tissue [PMCID: PMC4907409], we predicted the efficacy of…

HIGH LUNG LEVELS OF ACTIVE TRIPHOSPHATE PREDICTED WITH ORAL AT-527 IN COVID PATIENTS

AT-527 is a guanosine nucleotide prodrug with potent in vitro antiviral activity against flaviviruses and coronaviruses including SARS-CoV-2 (EC90=0.5 µM), the virus responsible for COVID-19. AT-527 exhibits a unique mechanism of action predominantly targeting the NiRAN function of the SARS-CoV-2 polymerase. The clinical safety to date and in vitro potency of AT-527 prompted evaluation of…

INTEGRATED DMPK ALGORITHM FOR THE PREDICTION OF ARV DDI MAGNITUDE

The prevalence of potential drug-drug interactions (DDIs) is about 29% in people living with HIV (PLWH) undergoing treatment, which can impact the overall management of therapies. Only a minority of potential DDIs have actually been characterised in clinical studies; many DDIs remain unexplored clinically or cannot be studied due to ethical constraints. In most cases,…

TFV-DP AND FTC-TP IN PBMC AMONG TRANSGENDER ADOLESCENTS RECEIVING DAILY TDF/FTC

Transgender women (TW) and transgender men (TM) have historically been underrepresented in pre-exposure prophylaxis (PrEP) clinical trials. Recently, a few studies have sought to address a potential drug-drug interaction between PrEP and cross-sex hormone therapy (csHT), but data remain limited, particularly among adolescent transgender individuals and TM. This was a prospective study conducted among adolescent…